Browse > Article

Gene Expression Profiling of 6-MP (6-mercaptopurine) in Liver  

Kim Hyung-Lae (Department of Biochemistry, College of Medicine, Ewha Womans University)
Kim Han-Na (Department of Biochemistry, College of Medicine, Ewha Womans University)
Lee Eun-Ju (Department of Biochemistry, College of Medicine, Ewha Womans University)
Publication Information
Genomics & Informatics / v.4, no.1, 2006 , pp. 16-22 More about this Journal
Abstract
The KFDA (Korea Food & Drug Administration) has performed a collaborative toxicogenomics project since 2003. Its aim is to construct a toxicology database of 12 compounds administered to mice at initial phase. We chose 6-MP (6-mercaptopurine) which has been used in the treatment of childhood leukemia. It was administered at low (0.224 mg/kg) and at high (2.24 mg/kg) dose (5 mice per group) intraperitonealy to the postnatal 6 weeks mice, then the serum and liver were collected at the indicated time (6, 24 and 72 h) after scarification. Serum biochemical markers for liver toxicity were measured and histopathologic studies also were carried out. The gene expression profiling was carried out by using Applied Biosystems 1700 Full Genome Expression Mouse. By self-organization maps (SOM), we identified groups with unique gene expression patterns, some of them are supposed to be related to 6-MP induced toxicity, including lipid metabolism abnormality, inflammatory response, oxidative stress, ATP depletion and cell death. The potential toxic effects appearing as gene expression changes are dependent of the time of 6-MP but independent of the dosage of it. This study would contribute to establishment of international database as well as national one about hepatotoxicity.
Keywords
6-Mercaptopurine (6-MP); acute hepatoxicity; microarray analysis; gene expression;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Farrell, G.C. (1994). Drug-Induced Liver Disease. Edinburgh: Churchill Livingstone
2 Lennard, L., Davies, H.A., and Lilleyman, J.S. (1993). Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia. Br. J. Cancer. 68, 186-190   DOI   ScienceOn
3 Michael, J., Tapner, Brett, E. Jones, Wan M. Wu, Geoffrey, C. and Farrell. (1974). Toxicity of low dose azathioprine and 6-mercaptopurine in rat hepatocytes. Roles of xanthine oxidase and mitochondrial injury. J. Hepatol. 40, 454-463   DOI   ScienceOn
4 Nygaard, U, Toft, N, and Schmiegelow, K. (2004). Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Clin. Pharmacol. Ther. 75, 274-281   DOI   ScienceOn
5 Schmiegelow, K. (1991). Prognostic significanceof methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia. Pediatr. Hematol. Oncol. 8, 301-312   DOI
6 Tapner, M.J., Jones, B.E, Wu, W.M., and Farrell, G.C. (2004). Toxicity of low dose azathioprine and 6-mercaptopurine in rat hepatocytes. Roles of xanthine oxidase and mitochondrial injury. J Hepatol. 40, 454-463   DOI   ScienceOn
7 Chung, H., Hong, D.P.,Jung, J.,Y., Kim, H.J.,Jang, K.S.,Sheen, Y.Y., Ahn, J.I., Lee, Y.S., and Kong, G.(2004). Comprehensive analysis of differential gene expression profiles on carbon tetrachlorideinduced rat liver injury and regeneration. Toxical. Appl. Pharmacal. 10,1016
8 Suffredini, .., Fantuzzi, G., Badolato, R., Oppenheim, J.J., and O'Grady, N.P. (1999). New insights into the biology of the acute phase response. J. Clin. Immunol. 19, 203-214   DOI   ScienceOn
9 Takikawa, H., Beppu, T., and Seyama, Y. (1984). Urinary concentrations of bile acid glucuronides and sulfates in hepatobiliary diseases. Gastroenterol. Jpn. 19, 104-109   DOI   ScienceOn
10 Berkovitch, M., Matsui, D., Zipursky, A., Blanchette, V.S., Verjee, Z., Giesbrecht, E., Saunders, E.F., Evans, W.E., and Koren, G. (1996). Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: pharmacokinetic characteristics. Med. Pediatr. Oncol. 26, 85-89   DOI   ScienceOn
11 Kim, J.E., Chang, H.Y., Park, D.Y., Lee, H.Y., Yoon, J.H., and Kim, S.N. (2005). A unique gene expression signature of 5-fluorouracil. Molecular&CeIluar Toxicol. 1. 248-255   과학기술학회마을
12 Burchenal, J.H., Murphy, M.L.,and Ellison, R.R. (1953).Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukaemia and allied diseases. Blood 8, 965-998
13 Phillips, M.J., Poucell, S., and ada, M.(1986). Mechanisms of cholestasis. Lab Invest. 54, 593-608
14 Schmiegelow, K. Prognostic significanceof methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia. Erratum in: Pediatr. Hematol. Oncol. (1992) 9, following 198
15 Ramadori, G., and Christ, B. (1999). Cytokinesand the hepatic acute-phase response. Semin. Liver Dis. 19, 141-155   DOI   ScienceOn
16 Makino, I.,Shinozaki,K., Nakagawa, S.,and Mashimo, K. (1974). Measurement of sulfated and nonsulfated bile acids in human serum and urine. J. Lipid Res. 15, 132-138
17 Heijne, W.H., Slitt, A.L., van Bladeren, P.J., Groten, J.P., Klaassen, C.D., Stierum, R.H., and van Ommen, B. (2004). Bromobenzene-induced hepatotoxicity at the transcriptome level. Toxieol. Sci. 79, 411-422   DOI   ScienceOn
18 Runnegar, M.T., Bemdt, N.,and Kaplowits, N. (1995). Microcystin uptake and inhibition of protein phosphatases: Effects of chemoprotectants and selfinhibition in relation to known hepatic transporter. Tox. Appl. Pharmacol. 134, 264-272   DOI   ScienceOn
19 Scheig, R. (1996). Evaluation of test used to screen patients with liver disorders. Prim. Care, 23, 551-560   DOI   ScienceOn